Efficacy and Safety of OnabotulinumtoxinA in Patients With Neurogenic Detrusor Overactivity Caused by Spinal Cord Injury: A Systematic Review and Meta-Analysis
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: OnabotulinumtoxinA (BoNT-A) is a promising therapy for treating neurogenic detrusor overactivity (NDO) in individuals with spinal cord injury (SCI). This systematic review and meta-analysis aimed to carry out an in-depth review and to make an objective estimation of the efficacy and safety of BoNT-A on NDO after SCI. Methods: The PubMed, Embase, and Cochrane databases were searched for all relevant articles published from 2001 to 2016 that referred to NDO, SCI, and BoNT-A or botulinum toxin A. All data were recorded in an Excel spreadsheet by 2 individual reviewers. Review Manager version 5.3 was used to carry out the meta-analysis. Results: This analysis included 17 studies involving 1,455 patients. Compared with placebo and baseline, BoNT-A was effective in increasing maximum cystometric capacity, volume at first involuntary detrusor contraction, cystometric bladder capacity (all P<0.00001), compliance (P=0.001), and the number of patients with complete dryness (P=0.0003), and decreasing detrusor pressure, the number of patients with no involuntary detrusor contractions, the maximum flow rate, the incidence of detrusor overactivity (all P<0.00001), and the number of urinary incontinence episodes (P=0.001). There were no statistically significant differences between doses of 200 U and 300 U or between injections into the detrusor and submucosa. There were no life-threatening adverse events. Conclusions: BoNT-A is effective and safe in treating NDO after SCI. There were no statistically significant differences between doses of 200 U and 300 U or between injecting into the detrusor and submucosa. However, more high-quality randomized controlled trials are still needed.
Abstract
Purpose: OnabotulinumtoxinA (BoNT-A) is a promising therapy for treating neurogenic detrusor overactivity (NDO) in individuals with spinal cord injury (SCI). This systematic review and meta-analysis aimed to carry out an in-depth review and to make an objective estimation of the efficacy and safety of BoNT-A on NDO after SCI. Methods: The PubMed, Embase, and Cochrane databases were searched for all relevant articles published from 2001 to 2016 that referred to NDO, SCI, and BoNT-A or botulinum toxin A. All data were recorded in an Excel spreadsheet by 2 individual reviewers. Review Manager version 5.3 was used to carry out the meta-analysis. Results: This analysis included 17 studies involving 1,455 patients. Compared with placebo and baseline, BoNT-A was effective in increasing maximum cystometric capacity, volume at first involuntary detrusor contraction, cystometric bladder capacity (all P<0.00001), compliance (P=0.001), and the number of patients with complete dryness (P=0.0003), and decreasing detrusor pressure, the number of patients with no involuntary detrusor contractions, the maximum flow rate, the incidence of detrusor overactivity (all P<0.00001), and the number of urinary incontinence episodes (P=0.001). There were no statistically significant differences between doses of 200 U and 300 U or between injections into the detrusor and submucosa. There were no life-threatening adverse events. Conclusions: BoNT-A is effective and safe in treating NDO after SCI. There were no statistically significant differences between doses of 200 U and 300 U or between injecting into the detrusor and submucosa. However, more high-quality randomized controlled trials are still needed.
참고문헌 (33)
- Leitner L, "Protocol for a prospective magnetic resonance imaging study on supraspinal lower urinary tract control in healthy subjects and spinal cord injury patients undergoing intradetrusor onabotulinumtoxinA injections for treating neurogenic detrusor overactivity", BMC Urol, 14, pp.68~ (2014)
- Tetreault LA, "The natural history of degenerative cervical myelopathy and the rate of hospitalization following spinal cord injury: an updated systematic review", Global Spine J, 7(3 Suppl), pp.28S~34S (2017)
- Hu HZ, "Pathophysiology, clinical importance, and management of neurogenic lower urinary tract dysfunction caused by suprasacral spinal cord injury", J Vet Intern Med, 30, pp.1575~1588 (2016)
- Schöps TF, "Neurogenic lower urinary tract dysfunction (NLUTD) in patients with spinal cord injury: long-term urodynamic findings", BJU Int, 115(Suppl 6), pp.33~38 (2015)
- Andy UU, "Validation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder", Neurourol Urodyn, 34, pp.424~428 (2015)
- Fergany LA, "Does sacral pulsed electromagnetic field therapy have a better effect than transcutaneous electrical nerve stimulation in patients with neurogenic overactive bladder?", Arab J Urol, 15, pp.148~152 (2017)
- Linsenmeyer TA, "Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review", J Spinal Cord Med, 36, pp.402~419 (2013)
- Yan HL, "Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials", Transplant Proc, 46, pp.1302~1313 (2014)
- regardless of concomitant anticholinergic use or neurologic etiology, "Adv Ther", 2013, 819~833
- Jia C, "Detrusor botulinum toxin A injection significantly decreased urinary tract infection in patients with traumatic spinal cord injury", Spinal Cord, 51, pp.487~490 (2013)
- Apostolidis A, "An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity", World J Urol, 31, pp.1469~1474 (2013)
- Sussman D, "Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity", Neurourol Urodyn, 32, pp.242~249 (2013)
- Cruz F, "Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial", Eur Urol, 60, pp.742~750 (2011)
- Ginsberg D, "Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity", J Urol, 187, pp.2131~2139 (2012)
- Sheng-Fu Chen, "Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder", Toxins, 8(6), pp.164~ (2016), MDPI AG[DOI]
- Hui C, "Combined detrusortrigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity", Spinal Cord, 54, pp.46~50 (2016)
- Sengoku A, "Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: multiinstitutional experience in Japan", Int J Urol, 22, pp.306~309 (2015)
- Chen YC, "The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients", Neurourol Urodyn, 33, pp.129~134 (2014)
- Krhut J, "Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study", Spinal Cord, 50, pp.904~907 (2012)
- Chen CY, "Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia", Spinal Cord, 49, pp.659~664 (2011)
- Gamé X, "Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections", Eur Urol, 53, pp.613~618 (2008)
- Klaphajone J, "Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions", Arch Phys Med Rehabil, 86, pp.2114~2118 (2005)
- Abdel-Meguid TA, "Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial", J Urol, 184, pp.2423~2428 (2010)
- Šámal V, "Submucosal administration of onabotulinumtoxinA in the treatment of neurogenic detrusor overactivity:pilot single-centre experience and comparison with standard injection into the detrusor", Urol Int, 91, pp.423~428 (2013)
- Herschorn S, "Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial", J Urol, 185, pp.2229~2235 (2011)
- Schurch B, "Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence", Eur Urol, 52, pp.850~858 (2007)
- Schurch B, "Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence", Arch Phys Med Rehabil, 88, pp.646~652 (2007)
- Schurch B, "Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study", J Urol, 174, pp.196~200 (2005)
- Zakin E, "Evidence on botulinum toxin in selected disorders", Toxicon, 147, pp.134~140 (2018)
- Smith CP, "Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions", Brain Res Bull, 61, pp.165~171 (2003)
- Nuanthaisong U, "Incidence of adverse events after high doses of onabotulinumtoxinA for multiple indications", Urology, 84, pp.1044~1048 (2014)
- Khera M, "Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury", Neurochem Int, 45, pp.987~993 (2004)
- Do TP, "Botulinum toxin: A review of the mode of action in migraine", Acta Neurol Scand, 137, pp.442~451 (2018)